Show simple item record

dc.contributor.authorChaudhary, B
dc.contributor.authorElkord, Eyad
dc.date.accessioned2016-10-04T10:46:33Z
dc.date.available2016-10-04T10:46:33Z
dc.date.issued2016
dc.identifier.citationRegulatory T Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. 2016, 4 (3): Vaccines (Basel)en
dc.identifier.issn2076-393X
dc.identifier.pmid27509527
dc.identifier.doi10.3390/vaccines4030028
dc.identifier.urihttp://hdl.handle.net/10541/619907
dc.description.abstractRecent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits.
dc.language.isoenen
dc.rightsArchived with thanks to Vaccinesen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleRegulatory T Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.en
dc.identifier.journalVaccinesen
refterms.dateFOA2018-12-17T14:39:03Z
html.description.abstractRecent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits.


Files in this item

Thumbnail
Name:
vaccines-04-00028-v2.pdf
Size:
525.2Kb
Format:
PDF
Description:
Open access full text article

This item appears in the following Collection(s)

Show simple item record

Archived with thanks to Vaccines
Except where otherwise noted, this item's license is described as Archived with thanks to Vaccines